Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Leflunomid - et nytt sykdomsmodifiserende antirevmatisk legemiddel
Engelsk titel: Leflunomide - a new disease modifying anti-rheumatic agent Läs online Författare: Rödevand E ; Kvien TK ; Johnsen V Språk: Nor Antal referenser: 14 Dokumenttyp: Översikt UI-nummer: 01111248

Tidskrift

Tidsskrift for Den Norske Laegeforening 2001;121(27)3181-4 ISSN 0029-2001 E-ISSN 0807-7096 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

BACKGROUND : Leflunomide is a novel disease-modifying antirheumatic drug (DMARD) for treatment of rheumatoid arthritis. The agent has been developed for the treatment of rheumatoid arthritis, but its multiple immunomodulatory properties may in the future be of interest in the treatment of other rheumatic and immunological diseases. MATERIAL AND METHODS : Review of the literature in order to present the current relevant clinical documentation of the drug. RESULTS : The clinical documentation is mainly based on three large, prospective, randomized trials of six months "to two years" duration comparing leflunomide with placebo, sulphasalazine or methotrexate. The efficacy of leflunomide in all trials was superior to placebo and comparable to sulphasalazine and methotrexate. The frequency of adverse events was also comparable to the comparators. INTERPRETATION : Leflunomide is a safe and efficacious addition to the roster of antirheumatic drugs, but further clinical trials and experience from clinical practice are needed in the evaluation of its place as a disease-modifying agent.